-
公开(公告)号：US10688412B2
公开(公告)日：2020-06-23
申请号：US15659093
申请日：2017-07-25
Applicant: Cephalon, Inc.
Inventor： Lu Wang , Tianyi Zhou , Zhaoqing Zhang , Mi Jin
IPC: B01D15/38 , C07K1/22 , C07K14/555 , C07K16/18 , C07K16/28
Abstract: A wash buffer comprising greater than 0 mM and less than about 500 mM arginine, greater than 0 mM and less than about 250 mM guanidine, greater than 0 mM and less than about 250 mM sodium chloride, and greater than 0 mM and less than about 50 mM of an anionic surfactant, or greater than 0% and less than about 0.25% w/v of a non-ionic surfactant. When used during affinity chromatography purification of a protein of interest, such as an antibody, the wash buffer significantly reduces the level of host cell proteins from the preparation. Following affinity chromatography with the wash buffer, the protein of interest may be further purified using membrane chromatography.
-
公开(公告)号：US20190106486A1
公开(公告)日：2019-04-11
申请号：US16164509
申请日：2018-10-18
Applicant: Cephalon, Inc.
Inventor： Lynn Dorothy Poulton , Matthew Pollard , Anthony G. Doyle , Bridget Ann Cooksey , Vanya Pande , Adam William Clarke
Abstract: Recombinantly expressed variant antibodies that have enhanced affinity for TL1A and enhanced potency relative to the parent antibody from which they were derived are provided. The antibodies inhibit the interaction between TL1A and the death receptor 3 (DR3). The antibodies, or a composition thereof, may be used to treat one or more of asthma, COPD, pulmonary fibrosis, cystic fibrosis, inflammatory bowel disease, a gastrointestinal disease associated with cystic fibrosis, Crohn's disease, colitis, ulcerative colitis, irritable bowel syndrome, eosinophilic esophagitis, atopic dermatitis, eczema, scleroderma, arthritis, or rheumatoid arthritis.
-
公开(公告)号：US20190046956A1
公开(公告)日：2019-02-14
申请号：US16014778
申请日：2018-06-21
Applicant: Cephalon, Inc.
Inventor： Lu WANG , Albert Kao , Zhaoqing Zhang , Mi Jin , Tianyi Zhou
Abstract: A wash buffer comprising a surfactant for use in affinity and cation exchange chromatography to purify proteins of interest from protein aggregates and to remove and/or inactivate viruses. When used during affinity or cation exchange chromatography for the purification of a protein of interest, such as an antibody, the wash buffer significantly improves viral clearance from the preparation, while also reducing the levels of host cell proteins and protein aggregates. Following affinity or cation exchange chromatography with the wash buffer, the protein of interest may be further purified using other chromatography and filtration operations.
-
公开(公告)号：US20180179159A1
公开(公告)日：2018-06-28
申请号：US15903150
申请日：2018-02-23
Applicant: Cephalon, Inc.
Inventor： Nadine C. Becknell , Reddeppa Reddy Dandu , Bruce D. Dorsey , Dimitar B. Gotchev , Robert L. Hudkins , Linda Weinberg , Craig A. Zificsak , Allison L. Zulli
IPC: C07D211/44 , C07D495/04 , C07D401/14 , C07D211/54 , C07D211/58 , C07D401/04 , C07D495/02 , C07D491/048 , C07D471/08 , C07D471/04 , C07D471/02 , C07D417/14 , C07D417/12 , C07D409/14 , C07D405/12 , C07D405/06 , C07D401/12 , C07D413/14 , C07D405/14 , C07D409/12
CPC classification number: C07D211/44 , C07D211/54 , C07D211/58 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/14 , C07D417/12 , C07D417/14 , C07D471/02 , C07D471/04 , C07D471/08 , C07D491/048 , C07D495/02 , C07D495/04
Abstract: Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses
-
公开(公告)号：US20170369451A1
公开(公告)日：2017-12-28
申请号：US15537954
申请日：2015-12-23
Applicant: CEPHALON, INC.
Inventor： Shawn P. ALLWEIN , Roger P. BAKALE , Dale R. MOWREY , Daniel E. PETRILLO , Sander KLUWER
IPC: C07D241/04 , A61K31/495
CPC classification number: C07D241/04 , A61K31/495 , C07D295/135 , C07D403/12
Abstract: The present disclosure is directed to improved methods useful for the preparation of, for example, 2-[[5-chloro-2-[[(6S)-6-[4-(2-hydroxyethyl)piperazin-1-yl]-1-methoxy-6,7,8,9-tetrahydro-5Hbenzo[7]annulen-2-yl]amino]pyrimidin-4-yl]amino]-N-methyl-benzamide (CEP-37440).
-
Patent Agency Ranking
公开(公告)号：US09623026B2
公开(公告)日：2017-04-18
申请号：US15146164
申请日：2016-05-04
Applicant: Cephalon, Inc.
Inventor： Shawn P. Allwein , Laurent Courvoisier , Martin J. Jacobs , Gregory R. Ott
IPC: A61K31/506 , C07D403/04 , C07D403/12
CPC classification number: A61K31/506 , C07D403/04 , C07D403/12
Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
-
公开(公告)号：US09533955B2
公开(公告)日：2017-01-03
申请号：US15045523
申请日：2016-02-17
Applicant: Cephalon, Inc.
Inventor： Martin Ian Cooper , Laurent D. Courvoisier , Mark Eddleston , Robert E. McKean
IPC: C07D235/16 , A61K31/4184 , A61K47/26 , A61K9/00 , A61K9/14 , A61K9/19
CPC classification number: A61K31/4184 , A61K9/0019 , A61K9/14 , A61K9/19 , A61K47/26 , C07D235/16
Abstract: Novel solid forms of bendamustine hydrochloride are described, as well as methods of their preparation and use.
Abstract translation: 描述了新型固体形式的盐酸苯达莫司汀，以及它们的制备和使用方法。
-
公开(公告)号：US09475766B2
公开(公告)日：2016-10-25
申请号：US13975483
申请日：2013-08-26
Inventor： Bruce D. Dorsey , Scott K. Kuwada , Jay P. Theroff , Craig A. Zificsak
IPC: A61K31/66 , A61K31/275 , A61K31/18 , A61K31/10 , C07C317/32 , C07C317/14 , C07C317/44 , C07D213/40 , C07D213/57 , C07D213/70 , C07D215/36 , C07D217/06 , C07D223/10 , C07D231/12 , C07D235/16 , C07D263/32 , C07D263/56 , C07D271/07 , C07D271/10 , C07D295/18 , C07D309/08 , C07D309/14 , C07D333/20 , C07D333/24 , C07D295/192
CPC classification number: C07C317/32 , C07C317/14 , C07C317/44 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07D213/40 , C07D213/57 , C07D213/70 , C07D213/71 , C07D215/36 , C07D217/06 , C07D223/10 , C07D223/12 , C07D231/12 , C07D235/06 , C07D235/16 , C07D263/32 , C07D263/56 , C07D263/57 , C07D271/07 , C07D271/10 , C07D295/18 , C07D295/185 , C07D295/192 , C07D309/08 , C07D309/14 , C07D333/20 , C07D333/24
Abstract: Compounds of formula II are described: wherein D, n, Ra, Rb, and Rc are as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.
Abstract translation: 其中D，n，Ra，Rb和Rc如本文所定义，以及使用式II化合物治疗或降低患者腹膜癌病变风险的药物组合物和方法。
-
![TREATMENT OF MULTIPLE SCLEROSIS WITH A 1,2,4-TRIAZOLO [1,5A] PYRIDINE DERIVATIVE](/abs-image/US/2016/10/20/US20160303116A1/abs.jpg.150x150.jpg)
29.发明申请TREATMENT OF MULTIPLE SCLEROSIS WITH A 1,2,4-TRIAZOLO [1,5A] PYRIDINE DERIVATIVE 审中-公开用1,2,4-三唑[1,5A]吡啶衍生物治疗多发性硬化症公开(公告)号：US20160303116A1
公开(公告)日：2016-10-20
申请号：US15102896
申请日：2014-12-10
Applicant: CEPHALON, INC.
Inventor： Pawel T. DOBRZANSKI , Joel KAYE , Arie ORBACH , Bruce A. RUGGERI , Matthew M. SEAVEY
IPC: A61K31/496 , A61K9/00
CPC classification number: A61K31/496 , A61K9/0053 , A61K31/437
Abstract: The present disclosure provides methods and compositions for treating chronic autoimmune diseases, such as multiple sclerosis, using [8-(4-methanesulfonyl-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-yl]-[3-(4-methyl-piperazin-1-yl)-phenyl]-amine or a pharmaceutically acceptable salt thereof.
Abstract translation: 本公开提供了使用[8-（4-甲磺酰基 - 苯基） - [1,2,4]三唑并[1,5-a]吡啶-2-基的治疗慢性自身免疫疾病如多发性硬化的方法和组合物 ] - [3-（4-甲基 - 哌嗪-1-基） - 苯基] - 胺或其药学上可接受的盐。
-
公开(公告)号：US09339502B2
公开(公告)日：2016-05-17
申请号：US14824750
申请日：2015-08-12
Applicant: Cephalon, Inc.
Inventor： Shawn P. Allwein , Laurent Courvoisier , Martin J. Jacobs , Gregory R. Ott
IPC: A61K31/506 , C07D403/04 , C07D403/12
CPC classification number: A61K31/506 , C07D403/04 , C07D403/12
Abstract: The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
-
-
-
-
-
-
-
-
-
Search Results
134
records
(took 0.042 seconds)
